EXACT Sciences Co. (NASDAQ:EXAS) CFO Jeffrey Thomas Elliott sold 8,746 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $95.58, for a total transaction of $835,942.68. Following the completion of the transaction, the chief financial officer now directly owns 59,109 shares in the company, valued at $5,649,638.22. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NASDAQ:EXAS opened at $94.75 on Friday. EXACT Sciences Co. has a 1-year low of $35.25 and a 1-year high of $123.31. The stock has a market cap of $14.68 billion, a P/E ratio of -89.39 and a beta of 1.89. The company has a debt-to-equity ratio of 0.64, a current ratio of 6.09 and a quick ratio of 5.81. The firm has a fifty day moving average price of $90.52 and a 200 day moving average price of $81.95.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Thursday, July 30th. The medical research company reported ($0.58) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.04. EXACT Sciences had a negative net margin of 13.65% and a negative return on equity of 14.49%. The company had revenue of $268.87 million during the quarter, compared to analysts’ expectations of $229.62 million. Sell-side analysts expect that EXACT Sciences Co. will post -1.63 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in EXAS. Vigilare Wealth Management acquired a new stake in shares of EXACT Sciences in the 4th quarter worth $293,000. Guggenheim Capital LLC lifted its stake in shares of EXACT Sciences by 29.5% in the fourth quarter. Guggenheim Capital LLC now owns 63,823 shares of the medical research company’s stock valued at $5,902,000 after purchasing an additional 14,554 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of EXACT Sciences by 67.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,818 shares of the medical research company’s stock valued at $1,562,000 after purchasing an additional 6,758 shares during the period. Standard Life Aberdeen plc lifted its stake in shares of EXACT Sciences by 6.4% in the fourth quarter. Standard Life Aberdeen plc now owns 18,108 shares of the medical research company’s stock valued at $1,674,000 after purchasing an additional 1,086 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of EXACT Sciences by 13.5% in the fourth quarter. Geode Capital Management LLC now owns 1,571,881 shares of the medical research company’s stock valued at $145,230,000 after purchasing an additional 186,817 shares during the period. Institutional investors own 86.66% of the company’s stock.

A number of research analysts recently commented on EXAS shares. Oppenheimer reaffirmed a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, July 8th. Benchmark increased their target price on shares of EXACT Sciences from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Friday. Robert W. Baird increased their target price on shares of EXACT Sciences from $90.00 to $92.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Canaccord Genuity dropped their target price on shares of EXACT Sciences from $120.00 to $110.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Finally, Bank of America increased their target price on shares of EXACT Sciences from $88.00 to $94.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Eighteen analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $105.80.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Article: Determine Your Level of Risk Tolerance

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.